c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

(2014) Bertrand Coiffier et al.   Journal of Hematology & Oncology

c-FLIP Protects Mature T Lymphocytes from TCR-Mediated Killing

(2014) N. Zhang et al.   JOURNAL OF IMMUNOLOGY

NIK Controls Classical and Alternative NF- B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells

(2013) L. Odqvist et al.   CLINICAL CANCER RESEARCH

Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation

(2013) Hui-ming Zhong et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma

(2013) Peter Reimer et al.   Journal of Hematology & Oncology

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

(2012) Makoto Kubo et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia

(2012) Donal McLornan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

(2012) Seok Jin Kim et al.   EUROPEAN JOURNAL OF CANCER

Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer

(2012) Simone Fulda   EXPERT OPINION ON THERAPEUTIC TARGETS

New molecular insights into peripheral T cell lymphomas

(2012) Stefano A. Pileri et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel therapeutic agents for cutaneous T-Cell lymphoma

(2012) Salvia Jain et al.   Journal of Hematology & Oncology

Apoptosis Induction by SAHA in Cutaneous T-Cell Lymphoma Cells Is Related to Downregulation of c-FLIP and Enhanced TRAIL Signaling

(2012) Nadya Al-Yacoub et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP

(2012) A Bangert et al.   ONCOGENE

ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2

(2011) Rosa Martín-Pérez et al.   APOPTOSIS

C/EBP  and C/EBP  oncoproteins regulate nfkb1 and displace histone deacetylases from NF- B p50 homodimers to induce NF- B target genes

(2011) I. Paz-Priel et al.   BLOOD

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment

(2011) Ryohei Furumai et al.   CANCER SCIENCE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo

(2009) Annika Lehmann et al.   BMC CANCER

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

(2009) Lena Marquard et al.   HISTOPATHOLOGY

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

(2009) Q-L Zhang et al.   LEUKEMIA

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research

(2009) E. S. Jaffe   Hematology-American Society of Hematology Education Program

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY